Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis

Area of Science:

• Neurology
• Immunology
• Endocrinology

Background:

• Observational studies suggest vitamin D may reduce inflammation in relapsing-remitting multiple sclerosis (RRMS).
• Randomized controlled trials (RCTs) have not yet confirmed these anti-inflammatory effects.
• High-dose vitamin D supplementation is being explored for its potential therapeutic benefits in RRMS.

Purpose of the Study:

• To investigate the anti-inflammatory effects of high-dose oral vitamin D3 in RRMS patients.
• To examine the impact of vitamin D3 supplementation on eleven systemic inflammation markers.
• To assess potential interactions between vitamin D3 and immunomodulatory therapies in RRMS.

Main Methods:

• A double-blinded, randomized, placebo-controlled trial (NCT00785473) involving 68 RRMS patients.
• Supplementation with 20,000 IU/week of vitamin D3 or placebo for 96 weeks.
• Measurement of serum inflammation markers and 25-hydroxyvitamin D (25(OH)D) at baseline and week 96.

Main Results:

• Vitamin D3 supplementation significantly increased serum 25(OH)D levels (56 to 123 nmol/L).
• No significant differences in inflammation markers were observed between the vitamin D3 and placebo groups.
• Patients on immunomodulatory therapy exhibited higher levels of specific inflammatory markers (IL-1RA, CXCL16) but no synergistic effect with vitamin D3.

Conclusions:

• High-dose oral vitamin D3 effectively increases serum 25(OH)D levels in RRMS patients.
• Vitamin D3 supplementation did not significantly alter systemic inflammation markers in this study.
• Immunomodulatory treatments were associated with an anti-inflammatory phenotype, independent of vitamin D status.